- EliV5 is developing a drug to fight fungal pathogens. New classes of anti-fungals are desperately needed, particularly with the emergence of multidrug resistant strains. To address this need, EliV5 Therapeutics is developing a new class of antifungals that disrupts a pathway critical for fungal survival.
- Invasive fungal infections create significant healthcare and economic burdens as they are responsible for more than one billion infections worldwide each year resulting in more than 1.5 million deaths. Hospital patients who acquire invasive fungal infections experience longer hospital stays, increased morbidity, and higher mortality rates. Only a few classes of antifungal drugs are available, and the emergence of resistance within all classes is an alarming threat to global public health.
- EliV5 is focusing on developing a drug to inhibit a target that controls major fungal cell activities. Clinical use of such a drug has the potential to provide a more effective therapeutic option for treating fungal infections and most importantly improving patient outcomes.
EliV5 Therapeutics founder, CEO and CSO, Choukri Ben Mamoun, PhD is an Associate Professor of Infectious Diseases at the Yale School of Medicine. He is a leading researcher in microbial pathogenesis. Choukri’s primary research focus is on unique and essential pathways used by eukaryotic pathogens that could be targeted for the development of new anti-microbials. At Yale, The Ben Mamoun Lab identified a novel target for anti-fungal therapy and discovered new classes of highly selective compounds, which in initial tests showed excellent biological activity and safety profiles. These chemicals are among several targets currently being pursued by EliV5 Therapeutics for further development as anti-microbials. Choukri received his PhD from the University of Paris XI and completed his Postdoctoral Fellowship at Washington University School of Medicine.
Jose Thekkiniath, PhD is the EliV5 Director of Research
Core EliV5 team members include Yale Center for Molecular Discovery PITCH scientists:
Yulia Surovtseva, PhD
Peter Gareiss, PhD
Denton Hoyer, PhD
William Hungerford, MS
In the News
EliV5 Therapeutics submitted an application for most recent STTR funding cycle.
Choukri Ben Mamoun, PhD, founder of EliV5 Therapeutics, scored big at the Yale Innovation Summit on May 8, 2019. The team won second prize, and an award of $5,000, in the Connecticut Innovations-sponsored Biotech Pitch Contest. EliV5 was selected by veteran investors in a competition including 36 Biotech electronic posters describing innovative, investigator-driven ventures. EliV5 team members shown above with the “big check” are (L to R) Marwan Azar, MD, Jose Thekkiniath, PhD, Denton Hoyer, PhD, Janie Merkel, PhD, Choukri Ben Mamoun, PhD, Pete Gareiss, PhD, and Francine Carland, PhD. Not pictured from the team: Yulia Surovtseva, PhD.